Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SciSparc Ltd. ( (SPRC) ) has provided an announcement.
On January 12, 2026, SciSparc Ltd. announced it had received a notice from Nasdaq stating that the company no longer met the exchange’s minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market, after previously reporting negative stockholders’ equity of about $81,000 as of June 30, 2025. SciSparc has until February 26, 2026 to submit a compliance plan and could receive up to 180 days from the notification date to regain compliance; in the meantime, its shares will continue to trade under the ticker SPRC, and the company indicated it expects to meet the equity threshold as of December 31, 2025, supported by capital from a debenture conversion in August 2025 and a registered direct offering completed in November 2025.
More about SciSparc Ltd.
SciSparc Ltd., listed on Nasdaq as SPRC, is a clinical-stage pharmaceutical company operating through its majority-owned subsidiary NeuroThera Labs Inc., focused on developing cannabinoid-based therapeutics. Its pipeline includes THC- and non-psychoactive CBD-based drug candidates such as SCI-110 for Tourette syndrome and for Alzheimer’s disease and agitation, and SCI-210 for autism spectrum disorder and status epilepticus, and it also holds a controlling interest in a business selling hemp seed oil-based products on Amazon.com.
Average Trading Volume: 1,400,077
Technical Sentiment Signal: Sell
Current Market Cap: $4.97M
See more data about SPRC stock on TipRanks’ Stock Analysis page.